List of Excipients in Branded Drug MEMANTINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	0591-3870	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	0591-3870	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	MEMANTINE HYDROCHLORIDE	memantine hydrochloride	0591-3870	FD&C BLUE NO. 2

Generic Drugs Containing MEMANTINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	memantine hydrochloride	0121-0850	ANHYDROUS CITRIC ACID
Pharmaceutical Associates Inc	memantine hydrochloride	0121-0850	GLYCERIN
Pharmaceutical Associates Inc	memantine hydrochloride	0121-0850	METHYLPARABEN

What are the Most Frequently-Used Excipients in MEMANTINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	ALCOHOL
4	ALUMINUM OXIDE
9	AMMONIA

Memantine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Memantine hydrochloride is a mature, genericized small-molecule Alzheimer’s drug with limited opportunity in conventional immediate-release tablets. The strongest commercial opportunities are differentiated oral delivery systems for older adults with dysphagia, including extended-release multiparticulates, sprinkle capsules, orally disintegrating tablets, taste-masked liquids, and fixed-dose combinations with donepezil. Excipient selection should prioritize swallowability, dose uniformity, stability, low gastrointestinal burden, and a manufacturing process that can support formulation patents or trade-secret protection.

What is the commercial status of memantine hydrochloride?

Memantine hydrochloride is an N-methyl-D-aspartate receptor antagonist approved for moderate-to-severe Alzheimer’s disease. In the United States, the reference products are Namenda immediate-release tablets and oral solution, and Namenda XR extended-release capsules. Memantine is also marketed with donepezil in Namzaric.

Product	Dosage form	Typical strengths	Commercial position
Namenda	Immediate-release tablet	5 mg, 10 mg	Generic competition established
Namenda	Oral solution	2 mg/mL	Niche use, administration flexibility
Namenda XR	Extended-release capsule	7 mg, 14 mg, 21 mg, 28 mg	Differentiated release profile; generic competition exists
Generic memantine IR	Tablets and solution	Equivalent to reference strengths	Price-led market
Generic memantine ER	Extended-release capsules	Equivalent to reference strengths	Formulation and manufacturing barriers remain
Namzaric	Donepezil/memantine ER capsule	Multiple strengths	Fixed-dose combination market

The FDA approved Namenda in 2003 and Namenda XR in 2010. Memantine hydrochloride is not a biologic, so biosimilar regulation under the Public Health Service Act does not apply. Competition proceeds through abbreviated new drug applications, 505(b)(2) applications, and, for combination products, separate product-specific pathways.[1][2]

What excipients are used in memantine hydrochloride products?

Memantine formulations use conventional excipients in immediate-release products and more specialized functional excipients in extended-release systems.

Immediate-release tablets

Representative memantine immediate-release tablets use:

• Lactose monohydrate
• Microcrystalline cellulose
• Talc
• Colloidal silicon dioxide
• Magnesium stearate

These excipients support direct compression or conventional granulation. The principal formulation risks are not API loading or solubility. Memantine hydrochloride is highly water soluble, so the commercial challenge is controlling release, tablet size, taste, and administration convenience.

For generic immediate-release tablets, excipient substitution is usually not commercially valuable unless it reduces manufacturing cost, improves robustness, or addresses a patient population with lactose intolerance, swallowing difficulty, or sensitivity to particular excipients.

Oral solution

Memantine oral solution products generally rely on:

• Sorbitol or another bulk sweetener
• Citric acid and sodium citrate for pH control
• Preservative systems such as potassium sorbate
• Purified water
• Flavoring agents, where permitted by the product design

The main technical risks are chemical stability, microbial control, palatability, preservative effectiveness, and dose measurement. Because memantine is intended for an elderly population, high sugar load, gastrointestinal tolerance, and compatibility with dosing syringes are important commercial considerations.

Extended-release capsules

Extended-release memantine products use multiparticulate or coated-pellet systems. Functional excipients may include:

• Sugar spheres or neutral starter cores
• Hypromellose or another film-forming polymer
• Ethylcellulose or a related rate-controlling polymer
• Povidone as a binder
• Talc as an anti-tacking or processing aid
• Polyethylene glycol or triethyl citrate as a plasticizer
• Gelatin or hypromellose capsule shells

The commercial value lies in the coating architecture rather than in any single excipient. Release can be modified through polymer selection, coating weight gain, pore-former content, pellet size, curing conditions, and capsule fill composition.

What excipient strategy is best for memantine hydrochloride?

The highest-value strategy is a platform approach that separates immediate-release, delayed-release, and sustained-release functions across multiparticulates.

Strategy 1: Multiparticulate extended release

A multiparticulate system can combine:

1. An immediate-release fraction for early exposure.
2. A sustained-release fraction coated with a water-insoluble polymer.
3. Optional uncoated pellets to tune the initial release phase.

This structure can support once-daily dosing while reducing the risk of dose dumping. It also allows capsule opening and sprinkling, provided the product maintains its release characteristics after administration with soft food.

Key formulation variables include:

Variable	Commercial or technical effect
Ethylcellulose coating	Controls diffusion-based release
Hypromellose coating	Supports hydration and gel formation
Plasticizer concentration	Influences film flexibility and permeability
Coating weight gain	Determines release duration
Pellet size distribution	Affects dose uniformity and dissolution
Capsule fill ratio	Affects delivered dose and packaging efficiency
Curing conditions	Changes polymer film structure and release reproducibility

A product that can be opened and sprinkled without crushing the pellets has greater value for patients with dysphagia. The labeling and performance claims must be supported by dissolution, stability, and in-use data.

Strategy 2: Taste-masked oral liquid

Memantine oral solution is already commercially available, so a new product would need a specific differentiation point. Candidate approaches include:

• Ion-pair or polymeric taste masking
• Cyclodextrin complexation
• Multiparticulate suspension
• Flavored, low-sugar formulation
• Preservative-free unit-dose packaging
• Ready-to-use oral syringe presentation

Taste masking is difficult because the active is highly water soluble. A conventional flavor-only approach may not sufficiently reduce bitterness. A polymer-coated microparticle or resin-based system can improve palatability, but the strategy must preserve rapid or intended release and avoid excessive excipient burden.

Strategy 3: Orally disintegrating tablet

An orally disintegrating tablet could target patients who cannot swallow conventional tablets. Useful excipients include:

• Crospovidone
• Croscarmellose sodium
• Low-substituted hydroxypropyl cellulose
• Mannitol
• Microcrystalline cellulose
• Copovidone
• Silicified microcrystalline cellulose

Mannitol can improve mouthfeel and cooling sensation. Crospovidone can produce rapid disintegration without excessive swelling. The primary risks are memantine’s bitter taste, tablet friability, moisture sensitivity, and the need to demonstrate bioequivalence or establish a new clinical bridge.

An orally disintegrating tablet is more commercially defensible when combined with taste masking, unit-dose packaging, and a clear administration advantage.

Strategy 4: Sprinkle capsule

A sprinkle capsule is potentially more valuable than a conventional capsule because it can serve patients who cannot swallow intact dosage forms. The formulation should use coated pellets that remain intact when mixed with soft food.

The critical requirements are:

• Uniform dose recovery after opening
• No pellet crushing during handling
• No significant change in dissolution after sprinkling
• Acceptable residence time on food
• Stability after exposure to humidity
• Clear instructions against chewing

This product can be positioned for long-term care facilities, home caregivers, and patients with swallowing impairment.

What formulation patents protect memantine hydrochloride products?

The original active-ingredient and early-use patent estate for memantine is expired in the United States. The commercial patent question concerns later-release systems, combination products, and specific delivery technologies.

Extended-release formulation patents

Namenda XR was protected by patents directed to extended-release memantine formulations and related dosage forms. Publicly identified U.S. patent families include U.S. Patent No. 8,741,904 and related continuation or divisional activity associated with extended-release memantine technology.[3]

The relevant claim categories generally include:

• Memantine-containing multiparticulates
• Polymer-coated particles
• Extended-release capsule dosage forms
• Defined dissolution profiles
• Once-daily administration
• Specific release-control compositions

Patent strength depends on claim scope. A patent limited to one coating polymer ratio may be vulnerable to design-around using a different polymer system. A patent that claims functional dissolution behavior across a broader composition range is more difficult to avoid but may face written-description, enablement, or obviousness challenges.

Method-of-use patents

Memantine method-of-use protection has less commercial importance than formulation protection because the core Alzheimer’s indication is established and generic competition is mature. Method claims can still matter where they cover:

• Specific titration regimens
• Combination use with donepezil
• Treatment of a defined patient subgroup
• Administration schedules linked to an extended-release product

Method-of-use claims may be addressed through a section viii statement or labeling carve-out where the applicant omits the patented indication from its proposed labeling. The practical value depends on whether the patented method is commercially central to the product.

Combination-product patents

Namzaric combines memantine extended release with donepezil. Combination patents may cover:

• Specific dose combinations
• Capsule architecture
• Co-packaged or single-capsule administration
• Release separation between donepezil and memantine
• Administration regimens

A combination product can retain commercial differentiation after the individual components become generic, but the market is exposed to substitution with separate generic products if prescribers and payers accept two-pill therapy.

When does memantine hydrochloride lose exclusivity?

Immediate-release memantine has already lost practical U.S. exclusivity. Generic immediate-release tablets and oral solution compete primarily on price, supply reliability, contract manufacturing, and payer access.

Exclusivity layer	Status
Original memantine active-ingredient protection	Expired
Original Alzheimer’s indication protection	Expired or commercially non-blocking
Immediate-release tablets	Generic competition established
Oral solution	Generic and alternative-product competition
Extended-release formulation protection	Later patents and regulatory listings have been more relevant
Donepezil/memantine combination	Separate combination-product patent and regulatory issues
Pediatric exclusivity	Not a central commercial factor for current memantine products

The exact patent and exclusivity position should be assessed against the current FDA Orange Book entries for the specific reference product and strength. FDA’s Orange Book is the controlling public source for listed patents, exclusivity codes, and patent certification analysis.[4]

What is the Orange Book and Paragraph IV risk for memantine?

For immediate-release memantine, Paragraph IV risk is limited because the primary market is already genericized. The more relevant risk applies to differentiated extended-release or combination products.

An ANDA applicant challenging a listed formulation patent may:

• File a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed.
• File a section viii statement and omit a patented method of use.
• Wait for patent expiry if the commercial launch opportunity does not justify litigation.
• Develop a non-infringing formulation with a materially different release-control system.

A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of approval under applicable conditions.[5] Commercial attractiveness depends on the size of the remaining branded market, the number of competing ANDA applicants, and whether the challenged patent covers the product’s core release architecture or a narrow embodiment.

Which companies are challenging or competing with branded memantine?

The U.S. memantine market includes generic manufacturers, contract development and manufacturing organizations, and companies with differentiated CNS delivery platforms. Generic competition has historically included large manufacturers such as Teva, Amneal, Lupin, Dr. Reddy’s Laboratories, Apotex, and others, depending on dosage form and market period.

The competitive landscape divides into four groups:

Competitor group	Main advantage	Main weakness
Generic IR tablet manufacturers	Low cost and simple CMC	Limited differentiation
Generic ER capsule manufacturers	Once-daily positioning	Multiparticulate manufacturing complexity
Combination-product manufacturers	Convenience and adherence	Higher formulation and patent costs
Specialty reformulation companies	Patient-centric delivery	Regulatory and reimbursement risk

The most defensible opportunity is not another standard 5 mg or 10 mg tablet. It is a product that reduces administration burden or improves adherence while maintaining a simple reimbursement narrative.

What manufacturing and intellectual-property barriers affect memantine?

Memantine itself presents limited API exclusivity barriers. The main manufacturing barriers are process control and product performance.

Manufacturing barriers

Important controls include:

• API particle-size distribution
• Blend uniformity at low dose
• Pellet layering efficiency
• Coating uniformity
• Residual solvent control
• Dissolution reproducibility
• Moisture protection
• Capsule fill-weight control
• Stability under long-term and accelerated conditions

The low dose of memantine in some products increases the importance of content uniformity. Multiparticulate systems introduce additional risks from segregation, electrostatic charging, pellet attrition, and coating defects.

Intellectual-property barriers

Excipients generally provide weak standalone patent protection. Stronger protection may come from:

• A defined pellet-core structure
• A non-obvious polymer combination
• A release profile linked to a specific clinical benefit
• A manufacturing sequence that produces a distinctive dissolution profile
• A sprinkle formulation with demonstrated post-opening performance
• A taste-masked particle architecture
• A combination of memantine and donepezil with separate release populations

Manufacturing know-how may provide more durable protection than a narrow formulation patent. Important trade secrets can include coating suspension composition, atomization conditions, curing temperature, fluid-bed parameters, and pellet classification criteria.

How does memantine compare with competing Alzheimer’s drugs?

Memantine is commercially distinct from monoclonal antibodies such as lecanemab and donanemab. Those products are biologics requiring infusion or injection and have different regulatory, manufacturing, and exclusivity profiles. Memantine remains an oral symptomatic therapy with low manufacturing cost and broad generic availability.

Attribute	Memantine hydrochloride	Lecanemab/donanemab class
Therapeutic role	Symptomatic treatment in moderate-to-severe disease	Disease-modifying treatment in earlier disease
Molecule type	Small molecule	Monoclonal antibody
Administration	Oral	Intravenous infusion
Biosimilar pathway	Not applicable	Potentially applicable
Main commercial barrier	Differentiated formulation and reimbursement	Clinical evidence, infusion capacity, safety monitoring
Excipient opportunity	High for oral delivery systems	Lower for conventional excipient differentiation

Memantine formulation opportunities are therefore driven by convenience, adherence, swallowing ability, and cost rather than by biologic comparability.

What regulatory pathway applies to new memantine formulations?

A conventional generic equivalent usually proceeds through an ANDA. A materially different dosage form, delivery profile, or combination may require a 505(b)(2) application.

Product concept	Likely pathway
Same-strength IR tablet with equivalent release	ANDA
Generic ER capsule matching reference profile	ANDA
New orally disintegrating tablet	ANDA only if equivalence criteria are satisfied; otherwise 505(b)(2)
New taste-masked liquid	Often 505(b)(2), depending on formulation and equivalence
New sprinkle capsule	ANDA or 505(b)(2), depending on reference-product comparability
Memantine/donepezil combination with new release architecture	505(b)(2) or combination-product pathway
New indication or materially different dosing regimen	505(b)(2) or supplemental application

FDA evaluation will focus on bioequivalence, comparative dissolution, food effects, dose proportionality, alcohol-induced dose dumping where relevant, stability, extractables and leachables, and patient-use performance. For an orally disintegrating or sprinkle product, administration instructions must be supported by performance data rather than assumed from the dosage form.[6]

What commercial opportunities exist for memantine excipients?

The best opportunities are formulation platforms that can be applied across CNS products rather than excipients sold solely for memantine.

High-potential opportunities

1. Taste-masking systems for highly soluble bitter APIs.
2. Coated multiparticulates that support capsule opening and sprinkling.
3. Low-sugar or sugar-free oral liquids for chronic use.
4. Rapidly disintegrating tablets with improved mouthfeel.
5. Moisture-resistant excipient systems for geriatric products.
6. Functional coating systems that reduce manufacturing cycle time.
7. Ready-to-use unit-dose oral delivery systems for institutional care.

Excipient suppliers can create value by offering prequalified systems with regulatory documentation, impurity profiles, toxicology packages, and process guidance. For memantine, the most commercially useful supplier proposition is a reproducible platform that reduces formulation-development time and supports a differentiated dosage form.

What generic launch scenarios exist for memantine?

Immediate-release launch

An IR tablet launch is low risk from a patent perspective but highly exposed to price erosion. Success depends on manufacturing cost, supply continuity, pharmacy distribution, and contracting.

Extended-release launch

An ER launch has greater technical value but requires careful assessment of listed patents, formulation similarity, dissolution performance, and potential Paragraph IV litigation. A design-around may be preferable to an aggressive patent challenge if the market has multiple approved generic entrants.

Differentiated 505(b)(2) launch

A new sprinkle, taste-masked, or orally disintegrating product could command a higher price if it demonstrates improved adherence or caregiver convenience. The principal commercial risk is payer refusal to reimburse a premium over low-cost generic tablets.

Institutional-care launch

Long-term care facilities may value unit-dose packaging, oral syringes, sprinkle administration, and reduced medication-administration time. This market can support specialized packaging and service models even when retail reimbursement is highly compressed.

Key Takeaways

• Memantine hydrochloride immediate-release products are mature generic products with limited conventional excipient upside.
• Extended-release multiparticulates remain the most technically meaningful formulation platform.
• Sprinkle capsules, orally disintegrating tablets, and taste-masked liquids address the strongest unmet administration needs.
• Excipients are more valuable as part of a protected formulation architecture than as standalone ingredients.
• The relevant patent risks center on extended-release systems, combination products, and method-of-use claims.
• Memantine has no biosimilar pathway because it is a small molecule.
• ANDA products face price competition; 505(b)(2) products need a clear clinical or administration advantage.
• Manufacturing know-how may provide stronger protection than narrow excipient claims.
• Commercial success depends on adherence, swallowing convenience, caregiver usability, and payer acceptance.

FAQs

Can memantine hydrochloride be formulated as a sustained-release suspension?

Yes. A sustained-release suspension could use coated microparticles or resin-based complexes, but physical stability, dose uniformity, syringe compatibility, sedimentation, and preservation would be major development issues.

Is a sugar-free memantine oral solution commercially attractive?

It can be attractive for chronic-use patients who need liquid administration, especially where sugar load or dental concerns matter. The product would need strong palatability, preservative performance, and a clear differentiation strategy against generic oral solution.

Can memantine extended-release pellets be sprinkled on food?

A sprinkle product is technically feasible if the pellets remain intact, retain dose uniformity, and preserve the intended dissolution profile after capsule opening. Chewing or crushing must be prevented through labeling and product design.

Are cyclodextrins suitable for memantine taste masking?

Cyclodextrins may improve palatability, but memantine’s high water solubility can limit complexation-driven masking. A coated-particle or polymeric barrier may provide stronger control.

What is the strongest patent strategy for a new memantine formulation?

The strongest strategy generally combines composition claims, functional release claims, administration claims, and manufacturing-process claims. A formulation with a demonstrated sprinkle, taste-masking, or adherence benefit is more commercially defensible than a simple excipient substitution.

References

1. U.S. Food and Drug Administration. (2003). Namenda (memantine hydrochloride) tablets prescribing information.

2. U.S. Food and Drug Administration. (2010). Namenda XR (memantine hydrochloride) extended-release capsules prescribing information.

3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,741,904, extended-release memantine formulations.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.

5. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards.

6. U.S. Food and Drug Administration. (2021). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry.